Efficacy and safety of switching from reference adalimumab to CT-P17 (100 mg/ml): 52-week randomised study in rheumatoid arthritis.
Daniel E FurstJanusz JaworskiRafal WojciechowskiPiotr WilandAnna DudekMarek KrogulecSlawomir JekaAgnieszka ZielinskaJakub TreflerKatarzyna Bartnicka-MaslowskaMagdalena Krajewska-WlodarczykPiotr A KlimiukSang Joon LeeSung Hyun KimYun Ju BaeGo Eun YangJae Kyoung YooJonathan KayEdward C KeystonePublished in: Rheumatology (Oxford, England) (2021)
Efficacy, pharmacokinetics, safety and immunogenicity of CT-P17 and reference adalimumab were comparable after 1 year of treatment, including after switching from reference adalimumab to CT-P17.
Keyphrases
- rheumatoid arthritis
- image quality
- dual energy
- computed tomography
- contrast enhanced
- juvenile idiopathic arthritis
- disease activity
- clinical trial
- positron emission tomography
- magnetic resonance imaging
- ulcerative colitis
- hidradenitis suppurativa
- open label
- interstitial lung disease
- study protocol
- combination therapy
- double blind